Sangmee Bae is a Rheumatology/Immunology physician affiliated with University of California, Los Angeles. OpenAlex indexes 39 publications with 6,704 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Ucla Medical Plz Ste 365b
Los Angeles, CA 900956932
Telephone
310-825-2448Registry record last updated 4 Dec 2019.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20252 payments
- Biogen, Inc.Program year20241 payment
- NOVARTIS PHARMACEUTICALS CORPORATIONProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
44.8%Corticosteroid44.8%Prednisone100%Part D≥13 patientsCancer & immunology
24.4%Folate Analog Metabolic Inhibitor11.6%Methotrexate100%Part D<11 patientsSelective T Cell Costimulation Modulator6.4%Orencia Clickject100%Part D<11 patients+ 1 more class in this area
Musculoskeletal
8.7%Nonsteroidal Anti-inflammatory Drug8.7%Diclofenac Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- Altered High-Density Lipoprotein function in Patients with Idiopathic Inflammatory Myopathies
University of California Los Angeles
FY2026$181,980K23AR081423 - Altered High-Density Lipoprotein function in Patients with Idiopathic Inflammatory Myopathies
University of California Los Angeles
FY2025$181,980K23AR081423 - Altered High-Density Lipoprotein function in Patients with Idiopathic Inflammatory Myopathies
University of California Los Angeles
FY2024$181,980K23AR081423
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”